TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Medivir AB ( (SE:MVIR) ).
Medivir AB’s partner, Vetbiolix, has announced the publication of landmark proof-of-concept clinical study results for VBX-1000, a treatment for canine periodontitis. The study, published in Frontiers in Veterinary Science, demonstrates the drug’s effectiveness in promoting alveolar bone healing and inhibiting cathepsin-K activity, highlighting its potential as a groundbreaking treatment. This development is significant for Medivir as it showcases the company’s successful out-licensing strategy, with potential financial benefits from milestone payments and royalties.
The most recent analyst rating on (SE:MVIR) stock is a Buy with a SEK54.00 price target. To see the full list of analyst forecasts on Medivir AB stock, see the SE:MVIR Stock Forecast page.
More about Medivir AB
Medivir AB is a pharmaceutical company focused on developing innovative treatments for cancer, particularly in areas with high unmet medical needs. The company emphasizes collaborations and partnerships as part of its business model, with a focus on developing fostroxacitabine bralpamide for liver cancer. Medivir is listed on Nasdaq Stockholm’s Small Cap list.
Average Trading Volume: 772,582
Technical Sentiment Signal: Sell
Current Market Cap: SEK50.47M
Learn more about MVIR stock on TipRanks’ Stock Analysis page.